Cencora, Inc. (NYSE:COR) is one of the stocks positioned for great growth. On March 24, UBS reiterated a Buy rating on Cencora, Inc. (NYSE:COR) with a price target of $410. The bullish stance is in response to the company’s announcement of its $1.1 billion acquisition of partner EyeSouth’s retina business.
Pressmaster/Shutterstock.com
The acquisition marks an important milestone as it expands Cencora’s presence in the specialty business by offering retina services. Additionally, the acquisition will be synergistic with RCA’s existing business, with all suppliers on board. It will also strengthen the company’s retina platform, which generated $600 million in revenue and $75 million in EBITDA in 2022.
The company will finance the transaction using existing credit lines and cash. The acquisition is also expected to be accretive to adjusted earnings per share in the first 12 months following closing. Analysts at Evercore ISI have also reiterated their optimism about the acquisition as a positive development. The analyst firm maintains an Outperform rating on the stock with a price target of $420.
Cencora, Inc. (NYSE:COR) is a leading global pharmaceutical solutions organization serving as a primary wholesale distributor connecting drug manufacturers with healthcare providers. It distributes branded, generic and specialty medications to hospitals, pharmacies and clinics, while providing logistics, supply chain optimization and marketing services for biopharmaceutical companies.
While we recognize COR’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: Top 30 S&P 500 Stocks by Index Weighting and the 10 best Ethereum stocks to buy now.
Disclosure: None. Follow Insider Monkey on Google News.